Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Type I IFN blockade uncouples immunotherapy-induced antitumor immunity and autoimmune toxicity.

Walsh SR, Bastin D, Chen L, Nguyen A, Storbeck CJ, Lefebvre C, Stojdl D, Bramson JL, Bell JC, Wan Y.

J Clin Invest. 2019 Feb 1;129(2):518-530. doi: 10.1172/JCI121004. Epub 2018 Dec 18.

2.

Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.

Kato D, Yaguchi T, Iwata T, Morii K, Nakagawa T, Nishimura R, Kawakami Y.

Nihon Rinsho Meneki Gakkai Kaishi. 2017;40(1):68-77. doi: 10.2177/jsci.40.68. Review.

3.

Ctla-4 blockade plus adoptive T-cell transfer promotes optimal melanoma immunity in mice.

Mahvi DA, Meyers JV, Tatar AJ, Contreras A, Suresh M, Leverson GE, Sen S, Cho CS.

J Immunother. 2015 Feb-Mar;38(2):54-61. doi: 10.1097/CJI.0000000000000064.

4.

Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.

Ascierto PA, Agarwala S, Botti G, Cesano A, Ciliberto G, Davies MA, Demaria S, Dummer R, Eggermont AM, Ferrone S, Fu YX, Gajewski TF, Garbe C, Huber V, Khleif S, Krauthammer M, Lo RS, Masucci G, Palmieri G, Postow M, Puzanov I, Silk A, Spranger S, Stroncek DF, Tarhini A, Taube JM, Testori A, Wang E, Wargo JA, Yee C, Zarour H, Zitvogel L, Fox BA, Mozzillo N, Marincola FM, Thurin M.

J Transl Med. 2016 Nov 15;14(1):313.

5.

Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma.

Rozera C, Cappellini GA, D'Agostino G, Santodonato L, Castiello L, Urbani F, Macchia I, Aricò E, Casorelli I, Sestili P, Montefiore E, Monque D, Carlei D, Napolitano M, Rizza P, Moschella F, Buccione C, Belli R, Proietti E, Pavan A, Marchetti P, Belardelli F, Capone I.

J Transl Med. 2015 May 2;13:139. doi: 10.1186/s12967-015-0473-5.

6.

The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment.

Pennock GK, Chow LQ.

Oncologist. 2015 Jul;20(7):812-22. doi: 10.1634/theoncologist.2014-0422. Epub 2015 Jun 11. Review.

7.

A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.

Takeda Y, Kataoka K, Yamagishi J, Ogawa S, Seya T, Matsumoto M.

Cell Rep. 2017 May 30;19(9):1874-1887. doi: 10.1016/j.celrep.2017.05.015.

8.

A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment.

Cauwels A, Van Lint S, Garcin G, Bultinck J, Paul F, Gerlo S, Van der Heyden J, Bordat Y, Catteeuw D, De Cauwer L, Rogge E, Verhee A, Uzé G, Tavernier J.

Oncoimmunology. 2017 Nov 27;7(3):e1398876. doi: 10.1080/2162402X.2017.1398876. eCollection 2018.

9.

Modulation of chemokines in the tumor microenvironment enhances oncolytic virotherapy for colorectal cancer.

Francis L, Guo ZS, Liu Z, Ravindranathan R, Urban JA, Sathaiah M, Magge D, Kalinski P, Bartlett DL.

Oncotarget. 2016 Apr 19;7(16):22174-85. doi: 10.18632/oncotarget.7907.

10.

Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager.

Wing A, Fajardo CA, Posey AD Jr, Shaw C, Da T, Young RM, Alemany R, June CH, Guedan S.

Cancer Immunol Res. 2018 May;6(5):605-616. doi: 10.1158/2326-6066.CIR-17-0314. Epub 2018 Mar 27.

11.

Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses.

Moynihan KD, Opel CF, Szeto GL, Tzeng A, Zhu EF, Engreitz JM, Williams RT, Rakhra K, Zhang MH, Rothschilds AM, Kumari S, Kelly RL, Kwan BH, Abraham W, Hu K, Mehta NK, Kauke MJ, Suh H, Cochran JR, Lauffenburger DA, Wittrup KD, Irvine DJ.

Nat Med. 2016 Dec;22(12):1402-1410. doi: 10.1038/nm.4200. Epub 2016 Oct 24.

12.

Adoptive transfer of Tc1 or Tc17 cells elicits antitumor immunity against established melanoma through distinct mechanisms.

Yu Y, Cho HI, Wang D, Kaosaard K, Anasetti C, Celis E, Yu XZ.

J Immunol. 2013 Feb 15;190(4):1873-81. doi: 10.4049/jimmunol.1201989. Epub 2013 Jan 11.

13.

Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy.

Kim S, Buchlis G, Fridlender ZG, Sun J, Kapoor V, Cheng G, Haas A, Cheung HK, Zhang X, Corbley M, Kaiser LR, Ling L, Albelda SM.

Cancer Res. 2008 Dec 15;68(24):10247-56. doi: 10.1158/0008-5472.CAN-08-1494.

14.

The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated mice.

Rommelfanger DM, Compte M, Diaz RM, Ilett E, Alvarez-Vallina L, Thompson JM, Kottke TJ, Melcher A, Vile RG.

Mol Ther. 2013 Feb;21(2):348-57. doi: 10.1038/mt.2012.204. Epub 2012 Sep 25. Erratum in: Mol Ther. 2013 Apr;21(4):913. Grau, Marta C [corrected to Compte, Marta].

15.

Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.

Guo Z, Wang H, Meng F, Li J, Zhang S.

J Transl Med. 2015 Jul 29;13:247. doi: 10.1186/s12967-015-0613-y.

16.

Effects of interferon-α-transduced tumor cell vaccines and blockade of programmed cell death-1 on the growth of established tumors.

Omori R, Eguchi J, Hiroishi K, Ishii S, Hiraide A, Sakaki M, Doi H, Kajiwara A, Ito T, Kogo M, Imawari M.

Cancer Gene Ther. 2012 Sep;19(9):637-43. doi: 10.1038/cgt.2012.42. Epub 2012 Jul 13.

PMID:
22790963
17.

Vaccine therapy of established tumors in the absence of autoimmunity.

Hodge JW, Grosenbach DW, Aarts WM, Poole DJ, Schlom J.

Clin Cancer Res. 2003 May;9(5):1837-49.

18.

Delivering Type I Interferon to Dendritic Cells Empowers Tumor Eradication and Immune Combination Treatments.

Cauwels A, Van Lint S, Paul F, Garcin G, De Koker S, Van Parys A, Wueest T, Gerlo S, Van der Heyden J, Bordat Y, Catteeuw D, Rogge E, Verhee A, Vandekerckhove B, Kley N, Uzé G, Tavernier J.

Cancer Res. 2018 Jan 15;78(2):463-474. doi: 10.1158/0008-5472.CAN-17-1980. Epub 2017 Nov 29.

19.

Emerging Role and Future Directions of Immunotherapy in Advanced Ovarian Cancer.

Chodon T, Lugade AA, Battaglia S, Odunsi K.

Hematol Oncol Clin North Am. 2018 Dec;32(6):1025-1039. doi: 10.1016/j.hoc.2018.07.011. Epub 2018 Oct 1. Review.

PMID:
30390758
20.

Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells.

John LB, Devaud C, Duong CP, Yong CS, Beavis PA, Haynes NM, Chow MT, Smyth MJ, Kershaw MH, Darcy PK.

Clin Cancer Res. 2013 Oct 15;19(20):5636-46. doi: 10.1158/1078-0432.CCR-13-0458. Epub 2013 Jul 19.

Supplemental Content

Support Center